Used in targeted cancer therapy, particularly for acute myeloid leukemia (AML). Binds selectively to CD33 antigen expressed on leukemic cells, enabling precise delivery of cytotoxic agents. Functions as a payload-conjugated antibody in antibody-drug conjugates (ADCs), enhancing tumor cell death while minimizing damage to healthy tissues. Shows potential in reducing relapse rates and improving outcomes in patients with minimal residual disease. Currently investigated in clinical trials for efficacy and safety in hematologic malignancies.